Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2010

Open Access 01-01-2010 | Article

Genetic association analysis of LARS2 with type 2 diabetes

Authors: E. Reiling, B. Jafar-Mohammadi, E. van ’t Riet, M. N. Weedon, J. V. van Vliet-Ostaptchouk, T. Hansen, R. Saxena, T. W. van Haeften, P. A. Arp, S. Das, G. Nijpels, M. J. Groenewoud, E. C. van Hove, A. G. Uitterlinden, J. W. A. Smit, A. D. Morris, A. S. F. Doney, C. N. A. Palmer, C. Guiducci, A. T. Hattersley, T. M. Frayling, O. Pedersen, P. E. Slagboom, D. M. Altshuler, L. Groop, J. A. Romijn, J. A. Maassen, M. H. Hofker, J. M. Dekker, M. I. McCarthy, L. M. ’t Hart

Published in: Diabetologia | Issue 1/2010

Login to get access

Abstract

Aims/hypothesis

LARS2 has been previously identified as a potential type 2 diabetes susceptibility gene through the low-frequency H324Q (rs71645922) variant (minor allele frequency [MAF] 3.0%). However, this association did not achieve genome-wide levels of significance. The aim of this study was to establish the true contribution of this variant and common variants in LARS2 (MAF > 5%) to type 2 diabetes risk.

Methods

We combined genome-wide association data (n = 10,128) from the DIAGRAM consortium with independent data derived from a tagging single nucleotide polymorphism (SNP) approach in Dutch individuals (n = 999) and took forward two SNPs of interest to replication in up to 11,163 Dutch participants (rs17637703 and rs952621). In addition, because inspection of genome-wide association study data identified a cluster of low-frequency variants with evidence of type 2 diabetes association, we attempted replication of rs9825041 (a proxy for this group) and the previously identified H324Q variant in up to 35,715 participants of European descent.

Results

No association between the common SNPs in LARS2 and type 2 diabetes was found. Our replication studies for the two low-frequency variants, rs9825041 and H324Q, failed to confirm an association with type 2 diabetes in Dutch, Scandinavian and UK samples (OR 1.03 [95% CI 0.95–1.12], p = 0.45, n = 31,962 and OR 0.99 [0.90–1.08], p = 0.78, n = 35,715 respectively).

Conclusions/interpretation

In this study, the largest study examining the role of sequence variants in LARS2 in type 2 diabetes susceptibility, we found no evidence to support previous data indicating a role in type 2 diabetes susceptibility.
Appendix
Available only for authorised users
Literature
1.
Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed
2.
Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950CrossRefPubMed
3.
Matschinsky FM, Glaser B, Magnuson MA (1998) Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 47:307–315CrossRefPubMed
4.
Maassen JA, Romijn JA, Heine RJ (2007) Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus. Diabetologia 50:2036–2041CrossRefPubMed
5.
van den Ouweland JM, Lemkes HH, Ruitenbeek W et al (1992) Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1:368–371CrossRefPubMed
6.
’t Hart LM, Hansen T, Rietveld I et al (2005) Evidence that the mitochondrial leucyl tRNA synthetase (LARS2) gene represents a novel type 2 diabetes susceptibility gene. Diabetes 54:1892–1895CrossRefPubMed
7.
Mooy JM, Grootenhuis PA, de Vries H et al (1995) Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273CrossRefPubMed
8.
World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus, report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. WHO, Geneva
9.
van 't Riet E, Rijkelijkhuizen JM, Nijpels G, Dekker JM (2008) Limited agreement between HbA1c and glucose in the general Dutch population: The New Hoorn Study. Diabetologia 51:S164–S164 (Abstract)
10.
Reiling E, van Vliet-Ostaptchouk JV, van 't Riet E et al (2009) Genetic association analysis of 13 nuclear-encoded mitochondrial candidate genes with type II diabetes mellitus: the DAMAGE study. Eur J Hum Genet 17:1056–1062CrossRefPubMed
11.
van Tilburg JH, Sandkuijl LA, Strengman E et al (2003) A genome-wide scan in type 2 diabetes mellitus provides independent replication of a susceptibility locus on 18p11 and suggests the existence of novel Loci on 2q12 and 19q13. J Clin Endocrinol Metab 88:2223–2230CrossRefPubMed
12.
Monsuur AJ, de Bakker PI, Alizadeh BZ et al (2005) Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 37:1341–1344CrossRefPubMed
13.
Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA (1991) Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7:403–422CrossRefPubMed
14.
Drivsholm T, Ibsen H, Schroll M, Davidsen M, Borch-Johnsen K (2001) Increasing prevalence of diabetes mellitus and impaired glucose tolerance among 60-year-old Danes. Diabet Med 18:126–132CrossRefPubMed
15.
Zeggini E, Weedon MN, Lindgren CM et al (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316:1336–1341CrossRefPubMed
16.
Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678CrossRef
17.
Florez JC, Sjogren M, Agapakis CM et al (2007) Association testing of common variants in the insulin receptor substrate-1 gene (IRS1) with type 2 diabetes. Diabetologia 50:1209–1217CrossRefPubMed
18.
Saxena R, Gianniny L, Burtt NP et al (2006) Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 55:2890–2895CrossRefPubMed
19.
Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40:638–645CrossRefPubMed
20.
Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P (2005) A haplotype map of the human genome. Nature 437:1299–1320CrossRef
21.
de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37:1217–1223CrossRefPubMed
22.
Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478–484CrossRefPubMed
23.
Bersaglieri T, Sabeti PC, Patterson N et al (2004) Genetic signatures of strong recent positive selection at the lactase gene. Am J Hum Genet 74:1111–1120CrossRefPubMed
24.
Coelho M, Luiselli D, Bertorelle G et al (2005) Microsatellite variation and evolution of human lactase persistence. Hum Genet 117:329–339CrossRefPubMed
25.
Sabeti PC, Schaffner SF, Fry B et al (2006) Positive natural selection in the human lineage. Science 312:1614–1620CrossRefPubMed
26.
Todd JA, Walker NM, Cooper JD et al (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39:857–864CrossRefPubMed
Metadata
Title
Genetic association analysis of LARS2 with type 2 diabetes
Authors
E. Reiling
B. Jafar-Mohammadi
E. van ’t Riet
M. N. Weedon
J. V. van Vliet-Ostaptchouk
T. Hansen
R. Saxena
T. W. van Haeften
P. A. Arp
S. Das
G. Nijpels
M. J. Groenewoud
E. C. van Hove
A. G. Uitterlinden
J. W. A. Smit
A. D. Morris
A. S. F. Doney
C. N. A. Palmer
C. Guiducci
A. T. Hattersley
T. M. Frayling
O. Pedersen
P. E. Slagboom
D. M. Altshuler
L. Groop
J. A. Romijn
J. A. Maassen
M. H. Hofker
J. M. Dekker
M. I. McCarthy
L. M. ’t Hart
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1557-7

Other articles of this Issue 1/2010

Diabetologia 1/2010 Go to the issue

Article

Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study

Article

Association of existing diabetes, gestational diabetes and glycosuria in pregnancy with macrosomia and offspring body mass index, waist and fat mass in later childhood: findings from a prospective pregnancy cohort

Article

Single pancreatic beta cells co-express multiple islet hormone genes in mice

Article

HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) study

Article

Differential relationship between physical activity and progression to diabetes by glucose tolerance status: the Inter99 Study

Short Communication

Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits